These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 12741439

  • 41. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
    Lodise TP, Lomaestro B, Graves J, Drusano GL.
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, Pogue JM, Rybak MJ.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [Abstract] [Full Text] [Related]

  • 46. Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: A data mining analysis using a decision tree model.
    Imai S, Yamada T, Kasashi K, Niinuma Y, Kobayashi M, Iseki K.
    J Eval Clin Pract; 2019 Feb; 25(1):163-170. PubMed ID: 30280456
    [Abstract] [Full Text] [Related]

  • 47. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
    Mousavi M, Zapolskaya T, Scipione MR, Louie E, Papadopoulos J, Dubrovskaya Y.
    Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
    [Abstract] [Full Text] [Related]

  • 48. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
    Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC.
    Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
    [Abstract] [Full Text] [Related]

  • 49. Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center.
    Marquis KA, DeGrado JR, Labonville S, Kubiak DW, Szumita PM.
    Ann Pharmacother; 2015 Sep; 49(9):1009-14. PubMed ID: 25991831
    [Abstract] [Full Text] [Related]

  • 50. Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing.
    Nakashima T, Koido K, Baba H, Otsuka R, Okinaka K, Sano T, Nishigaki R, Hashimoto H, Otsuka T, Esaki M, Terakado H.
    Pharmazie; 2018 Jul 01; 73(7):422-424. PubMed ID: 30001779
    [Abstract] [Full Text] [Related]

  • 51. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
    Ringenberg T, Robinson C, Meyers R, Degnan L, Shah P, Siu A, Sturgill M.
    Pediatr Infect Dis J; 2015 Jul 01; 34(7):742-7. PubMed ID: 25629890
    [Abstract] [Full Text] [Related]

  • 52. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
    Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E.
    Anesthesiology; 2009 Aug 01; 111(2):356-65. PubMed ID: 19602966
    [Abstract] [Full Text] [Related]

  • 53. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
    Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, Falcione B, Rybak MJ.
    Pharmacotherapy; 2011 May 01; 31(5):441-8. PubMed ID: 21923425
    [Abstract] [Full Text] [Related]

  • 54. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity.
    Choi YC, Saw S, Soliman D, Bingham AL, Pontiggia L, Hunter K, Chuang L, Siemianowski LA, Ereshefsky B, Hollands JM.
    Ann Pharmacother; 2017 Nov 01; 51(11):937-944. PubMed ID: 28709394
    [Abstract] [Full Text] [Related]

  • 55. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME.
    Expert Opin Drug Saf; 2010 Jan 01; 9(1):9-14. PubMed ID: 20021290
    [Abstract] [Full Text] [Related]

  • 56. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
    Pea F, Porreca L, Baraldo M, Furlanut M.
    J Antimicrob Chemother; 2000 Mar 01; 45(3):329-35. PubMed ID: 10702552
    [Abstract] [Full Text] [Related]

  • 57. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS, Sorensen SV, Liu LZ, Itani KM.
    Ann Pharmacother; 2006 Jun 01; 40(6):1017-23. PubMed ID: 16720705
    [Abstract] [Full Text] [Related]

  • 58. Incidence and predictors of vancomycin-associated nephrotoxicity.
    Moh'd H, Kheir F, Kong L, Du P, Farag H, Mohamad A, Zurlo JJ.
    South Med J; 2014 Jun 01; 107(6):383-8. PubMed ID: 24945176
    [Abstract] [Full Text] [Related]

  • 59. Evaluation of Treatment Courses When Vancomycin Is Given Every 8 Hours in Adult Patients.
    Brumer E, Dubrovskaya Y, Scipione MR, Aberle C, Rahimian J, Papadopoulos J.
    J Pharm Pract; 2015 Dec 01; 28(6):511-7. PubMed ID: 25112304
    [Abstract] [Full Text] [Related]

  • 60. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?
    Kralovicová K, Spanik S, Halko J, Netriova J, Studena-Mrazova M, Novotny J, Grausova S, Koren P, Krupova I, Demitrovicova A, Kukuckova E, Krcmery V.
    J Chemother; 1997 Dec 01; 9(6):420-6. PubMed ID: 9491842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.